No Data
No Data
Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 48.32 Yuan From 51.12 Yuan, Keeps at Neutral
Jiangsu Hengrui Medicine Gets Clinical Trial Approval for Liver Disease Treatment
Jiangsu Hengrui Pharmaceuticals (600276.SH): Hydroxyethylsulfonate Dalsilepin tablets and HRS-1358 tablets have obtained drug clinical trial approval.
On July 21st, Gelunhui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) and its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. recently received the Approval Notice for Clinical Trials of Hydroxyethanesulfonic Acid Daxcelipine Tablets and HRS-1358 Tablets issued by the National Medical Products Administration, and will conduct clinical trials in the near future. Hydroxyethanesulfonic Acid Daxcelipine Tablets (trade name: Airicon) has been approved for two indications, respectively: in December 2021, it was approved for use in combination with Fluvestrant for Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer patients who have undergone endocrine therapy.
Zhao Bei's second-quarter report for ICBC Credit Suisse Fund has been released! Jiangsu Hengrui Pharmaceuticals (600276.SH) is the top holding.
On July 18th, the fund under Zhao Bei's management at ICBC Credit Suisse Fund released its Q2 report for 2024.
Ping An Securities: Nuclear medicine has multiple clinical advantages, and high barriers to entry have created an oligopolistic monopoly pattern.
It is expected that from 2023 to 2030, China's nuclear medicine market will grow from 5 billion yuan to 26 billion yuan at a CAGR of 26.6%.
Market Chatter: Jiangsu Hengrui Medicine Vows to Improve Production Following FDA Warning
No Data